List of works - Lotte Bjerre Knudsen

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.

scientific article published on April 2011

A genetic map of the mouse dorsal vagal complex and its role in obesity

scientific article published on 25 March 2021

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

scientific article

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease

scientific article published on 24 May 2016

Characterization of the glucagon-like peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization.

scientific article published on 30 October 2017

Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats

scientific article published on 9 July 2010

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

scientific article published in April 2008

Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop

scientific article published on May 2014

Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.

scientific article published on December 2013

Corrigendum to “Functional importance of GLP-1 receptor species and expression levels in cell lines” [Regul. Pept. 175 (2012) 21–29]

article

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor

scientific article

Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor.

scientific article published on 14 September 2013

Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

scientific article published on December 1998

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

scientific article

Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.

scientific article

Expression of the GLP-1 receptor in mouse, rat, and human pancreas

scientific article published on 9 June 2008

Functional importance of GLP-1 receptor species and expression levels in cell lines.

scientific article published on 15 January 2012

GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation.

scientific article published on September 2016

GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress

scientific article published on 26 November 2011

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

scientific article published on 29 July 2003

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

scientific article published on 10 January 2012

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

scientific article published on 27 January 2014

GLP-1 regulates the POMC neurons of the arcuate nucleus both directly and indirectly via presynaptic action

scientific article published on 05 November 2020

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

scientific article

Glucagon-like peptide-1 receptor expression in the human eye.

scientific article

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

scientific article published on 01 December 1996

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

scientific article published in August 2004

Human glucagon receptor antagonists based on alkylidene hydrazides

scientific article published in February 2002

Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.

scientific article published in May 2009

Identification of alkylidene hydrazides as glucagon receptor antagonists.

scientific article

Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.

scientific article published on 17 January 2017

Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment

scientific article published in Scientific Reports

Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity

scientific article published on 20 August 2019

Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling

scientific article

Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease

scientific article published on 02 September 2020

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

scientific article published in January 2007

Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.

scientific article published on 29 May 2008

Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture

scientific article published on 12 October 2009

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

scientific article published in July 2007

Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus

scientific article published on 30 December 2009

Liraglutide: the therapeutic promise from animal models.

scientific article published on October 2010

Lixisenatide in the treatment of Type 2 diabetes

scientific article published on 29 March 2014

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease

scientific article

Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus

scientific article

Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.

scientific article published on 27 May 2010

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

scientific article published in September 2002

New beta-alanine derivatives are orally available glucagon receptor antagonists

scientific article

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

scientific article

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

scientific article

Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide.

scientific article published on 8 January 2009

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

scientific article

Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease

scientific article published on 22 November 2019

Semaglutide lowers body weight in rodents via distributed neural pathways

scientific article published on 26 March 2020

Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor

article

Small-molecule agonists for the glucagon-like peptide 1 receptor

scholarly article

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

scientific article published on 2 November 2007

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

scientific article published in November 2001

The Discovery and Development of Liraglutide and Semaglutide

article

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways.

scientific article published on 21 November 2018

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.

scientific article published on 13 April 2015

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy

scientific article published on 30 December 2015

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

scientific article

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

scientific article published on 15 May 2012

The glucagon-like peptide-1 receptor--or not?

scientific article

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

scientific article published on 14 February 2012

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

scientific article published on 7 March 2014

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

scientific article

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

scientific article published in May 2005

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.

scientific article published on 25 June 2008

The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist

scientific article

Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus

scientific article (publication date: 25 July 2003)

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

scientific article published on 01 November 2018

Transmembrane α-Helix 2 and 7 Are Important for Small Molecule-Mediated Activation of the GLP-1 Receptor

scientific article published on 30 November 2011

List of works by Lotte Bjerre Knudsen

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.

A genetic map of the mouse dorsal vagal complex and its role in obesity

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease

Characterization of the glucagon-like peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization.

Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.

Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop

Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.

Corrigendum to “Functional importance of GLP-1 receptor species and expression levels in cell lines” [Regul. Pept. 175 (2012) 21–29]

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor

Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor.

Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.

Expression of the GLP-1 receptor in mouse, rat, and human pancreas

Functional importance of GLP-1 receptor species and expression levels in cell lines.

GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation.

GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

GLP-1 regulates the POMC neurons of the arcuate nucleus both directly and indirectly via presynaptic action

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Glucagon-like peptide-1 receptor expression in the human eye.

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

Human glucagon receptor antagonists based on alkylidene hydrazides

Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.

Identification of alkylidene hydrazides as glucagon receptor antagonists.

Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.

Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment

Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity

Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling

Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice.

Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture

Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs.

Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus

Liraglutide: the therapeutic promise from animal models.

Lixisenatide in the treatment of Type 2 diabetes

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease

Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus

Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

New beta-alanine derivatives are orally available glucagon receptor antagonists

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide.

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease

Semaglutide lowers body weight in rodents via distributed neural pathways

Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor

Small-molecule agonists for the glucagon-like peptide 1 receptor

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

The Discovery and Development of Liraglutide and Semaglutide

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways.

The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

The glucagon-like peptide-1 receptor--or not?

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.

The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist

Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

Transmembrane α-Helix 2 and 7 Are Important for Small Molecule-Mediated Activation of the GLP-1 Receptor